PTC Therapeutics | PTCT - Sales Revenues

Stock Price
72.73
Daily Change
-1.18 -1.60%
Monthly
-5.18%
Yearly
46.07%
Q1 Forecast
73.20

PTC Therapeutics reported $211M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 278.6M 14M Sep/2025
Alnylam Pharmaceuticals USD 1.25B 476.31M Sep/2025
Amgen USD 9.9B 340M Dec/2025
Biogen USD 2.53B 70M Sep/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Cytokinetics USD 1.93M 64.83M Sep/2025
Daiichi Sankyo JPY 558.11B 57.35B Dec/2025
Gilead Sciences USD 7.8B 700M Sep/2025
Incyte USD 1.37B 310M Sep/2025
Ionis Pharmaceuticals USD 157M 295M Sep/2025
Ironwood Pharmaceuticals USD 122.06M 36.82M Sep/2025
Novartis USD 13.91B 144M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 211M 32.1M Sep/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
TG Therapeutics USD 161.7M 20.6M Sep/2025
Ultragenyx Pharmaceutical USD 160M 6.5M Sep/2025
Vertex Pharmaceuticals USD 3.08B 120M Sep/2025
Xencor USD 21M 22.61M Sep/2025